SCHEMBL2187463

SCHEMBL2187463

CN1CCCN([C@H]2Cc3c(Cl)cc(Cl)cc3[C@H]2Oc2ccc(S(C)(=O)=O)cc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
SLC9A3 P48764 20/20 1.00
CYP2D6 P10635 2/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2189853 1.00 SLC9A3 (1.00) SLC9A3CYP2D6
SCHEMBL2186573 1.00 SLC9A3 (1.00) SLC9A3CYP2D6
SCHEMBL2187900 0.96 SLC9A3 (1.00) SLC9A3CYP2D6
SCHEMBL2187898 0.96 SLC9A3 (1.00) SLC9A3CYP2D6
SCHEMBL2188283 0.93 SLC9A3 (0.87) SLC9A3CYP2D6
SCHEMBL2258688 0.88 SLC9A3 (0.85) SLC9A3CYP2D6
SCHEMBL2258691 0.88 SLC9A3 (0.85) SLC9A3CYP2D6
SCHEMBL2214284 0.88 SLC9A3 (0.85) SLC9A3CYP2D6
SCHEMBL2187062 0.87 SLC9A3 (0.84) SLC9A3CYP2D6
SCHEMBL2188710 0.87 SLC9A3 (1.00) SLC9A3CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342178-B1 SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF SANOFI SA (FR) 2016-09-28 EP claimed
US-8822449-B2 Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof SANOFI (FR) 2014-09-02 US claimed
US-20110201590-A1 SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF SANOFI-AVENTIS (FR) 2011-08-18 US claimed
EP-2342178-A1 SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF Sanofi-Aventis (FR) 2011-07-13 EP claimed
WO-2010025856-A1 SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF SANOFI-AVENTIS (FR) 2010-03-11 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201590-A1 SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF CFTR, AADAT, PKD1 SLC9A3 750/4885CYP2D6 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.